GRAIL, Inc. (Nasdaq: GRAL) — Research Summary

As of late October 2026, GRAIL is a commercial-stage biotechnology/diagnostics company (spun off from Illumina in June 2024) whose core product, the Galleri multi-cancer early detection (MCED) blood test, trades near multi-month highs after a pivotal FDA regulatory development [11], [27]. Below is a point-in-time synthesis of recent catalysts, narratives, risks, and scheduled events, with sources cited. Where sources conflict, I flag the discrepancy.

Recent Catalysts (last ~1–3 months)